Grant A McArthur
Overview
Explore the profile of Grant A McArthur including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
222
Citations
22571
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Long G, Atkinson V, Lo S, Guminski A, Sandhu S, Brown M, et al.
Lancet Oncol
. 2025 Feb;
26(3):320-330.
PMID: 39978375
Background: Patients with melanoma brain metastases respond well to immunotherapy, but long-term comparative survival data are scarce. We aimed to assess the efficacy of ipilimumab plus nivolumab versus nivolumab alone...
2.
Woodford R, McKeown J, Hoeijmakers L, Mangana J, Dimitriou F, Allayous C, et al.
Eur J Cancer
. 2024 Oct;
212:115055.
PMID: 39366209
Introduction: Approximately 50 % of resected stage II-IV melanoma patients develop recurrent disease by 5 years despite adjuvant anti-PD-1 therapy. Data to define best management of recurrences is lacking. Methods:...
3.
Soon J, Franchini F, IJzerman M, McArthur G
Nat Cancer
. 2024 Sep;
5(11):1597-1599.
PMID: 39304773
No abstract available.
4.
Sturm R, Smit D, Duffy D, McLean C, Scolyer R, McArthur G, et al.
Br J Dermatol
. 2024 Aug;
192(1):55-62.
PMID: 39166481
Background: Approximately 2-20% of cutaneous melanomas (CMs) are diagnosed as amelanotic/hypopigmented melanoma (AHM) and represent a challenge for early diagnosis. Objectives: To investigate loss-of-function mutations in key pigmentation genes in...
5.
Cameron D, Sornkom J, Alsahafi S, Drygin D, Poortinga G, McArthur G, et al.
Biomedicines
. 2024 Jul;
12(7).
PMID: 39062087
While genotoxic chemotherapeutic agents are among the most effective tools to combat cancer, they are often associated with severe adverse effects caused by indiscriminate DNA damage in non-tumor tissue as...
6.
Menzies A, Long G, Kohn A, Tawbi H, Weber J, Flaherty K, et al.
Neurooncol Adv
. 2024 May;
6(1):vdae033.
PMID: 38725995
Background: POLARIS (phase 2 [ph2]; NCT03911869) evaluated encorafenib (BRAF inhibitor) in combination with binimetinib (MEK1/2 inhibitor) in BRAF/MEK inhibitor-naïve patients with V600-mutant melanoma with asymptomatic brain metastases. Methods: The safety...
7.
Knight D, Ngiow S, Li M, Parmenter T, Mok S, Cass A, et al.
J Clin Invest
. 2023 Dec;
133(24).
PMID: 38099495
No abstract available.
8.
Soon J, To Y, Alexander M, Trapani K, Ascierto P, Athan S, et al.
J Cancer Policy
. 2023 Nov;
38:100441.
PMID: 38008488
Background: Horizon scanning (HS) is the systematic identification of emerging therapies to inform policy and decision-makers. We developed an agile and tailored HS methodology that combined multi-criteria decision analysis weighting...
9.
Ewen T, Husain A, Stefanos N, Barrett P, Jones C, Ness T, et al.
Br J Dermatol
. 2023 Nov;
190(4):549-558.
PMID: 38006317
Background: Combined expression of the autophagy-regulatory protein AMBRA1 (activating molecule in Beclin1-regulated autophagy) and the terminal differentiation marker loricrin in the peritumoral epidermis of stage I melanomas can identify tumour...
10.
Lasocki A, Stuckey S, Caspersz L, Xie J, McArthur G
AJNR Am J Neuroradiol
. 2023 Aug;
44(9):1039-1044.
PMID: 37620155
Background And Purpose: Volumetric TSE (3D-TSE) techniques are increasingly replacing volumetric magnetization-prepared gradient recalled-echo (3D-GRE) sequences due to improved metastasis detection. In addition to providing a baseline for assessing postcontrast...